Lack of effect of enalaprilat on the action of vasoactive intestinal polypeptide in the human forearm.
It has been proposed that angiotensin converting enzyme (ACE) may play a role in the metabolism of the vasodilator peptide vasoactive intestinal polypeptide (VIP). Reduced metabolism following treatment with ACE inhibitors may cause accumulation of VIP which in turn may mediate some of the beneficial haemodynamic effects of ACE inhibition observed in patients with heart failure. This study has shown that inhibition of local vascular ACE does not interfere with the vascular effects of VIP on forearm resistance vessels when this peptide is infused into the brachial artery of normal volunteers. These results suggest that endothelial ACE plays little part in the metabolism of intravascular VIP.
Cockcroft
J R
JR
Department of Clinical Pharmacology, Guy's Hospital Medical School, London.
Chowienczyk
P
P
Elliott
T G
TG
Ritter
J M
JM
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D015773:Enalaprilat / Q000008:administration & dosage / Q000494:pharmacology*; D005542:Forearm / Q000098:blood supply*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D012039:Regional Blood Flow / Q000187:drug effects; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*; D014664:Vasodilation / Q000187:drug effects
D014660:Vasoactive Intestinal Peptide; D015773:Enalaprilat